AIER EYE HOSPITAL GROUP CO., LTD. Financials Aier Eye Hospital Group Co., Ltd.
Equities
300015
CNE100000GR6
Healthcare Facilities & Services
|
End-of-day quote
Other stock markets
|
5-day change | 1st Jan Change | ||
| 12.63 CNY | +3.19% |
|
+4.04% | -20.16% |
| Apr. 26 | Aier Eye Hospital Group Co., Ltd. Announces Profit Distribution Proposal for 2023 | CI |
| Apr. 26 | Nomura Adjusts Aier Eye Hospital's Price Target to 15.35 Yuan From 22.14 Yuan, Keeps at Buy | MT |
Valuation
| Fiscal Period: December | 2019 | 2020 | 2021 | 2022 | 2023 | 2024 | 2025 | 2026 |
|---|---|---|---|---|---|---|---|---|
| Capitalization 1 | 122,549 | 308,658 | 228,569 | 222,975 | 147,575 | 117,441 | - | - |
| Enterprise Value (EV) 1 | 123,233 | 307,677 | 226,545 | 218,198 | 143,117 | 109,203 | 107,693 | 102,823 |
| P/E ratio | 88.6 x | 177 x | 97.6 x | 85.1 x | 43.6 x | 30.2 x | 22.3 x | 21.4 x |
| Yield | 0.38% | 0.2% | 0.28% | 0.32% | 0.95% | 1.19% | 1.59% | 1.75% |
| Capitalization / Revenue | 12.3 x | 25.9 x | 15.2 x | 13.8 x | 7.25 x | 5.1 x | 3.95 x | 3.83 x |
| EV / Revenue | 12.3 x | 25.8 x | 15.1 x | 13.5 x | 7.03 x | 4.74 x | 3.62 x | 3.35 x |
| EV / EBITDA | 48.8 x | 95.4 x | 54.5 x | - | 24 x | 15.5 x | 12.7 x | 11 x |
| EV / FCF | 92.1 x | 125 x | 87.3 x | 70.2 x | 32.4 x | 21.3 x | 20.9 x | 17.2 x |
| FCF Yield | 1.09% | 0.8% | 1.15% | 1.43% | 3.09% | 4.69% | 4.78% | 5.8% |
| Price to Book | 18.6 x | 31.3 x | 20.2 x | 13.4 x | 7.83 x | 5.52 x | 4.28 x | 4.19 x |
| Nbr of stocks (in thousands) | 8,818,703 | 9,025,341 | 9,130,452 | 9,329,492 | 9,328,411 | 9,298,537 | - | - |
| Reference price 2 | 13.90 | 34.20 | 25.03 | 23.90 | 15.82 | 12.63 | 12.63 | 12.63 |
| Announcement Date | 2/28/20 | 4/22/21 | 4/25/22 | 4/25/23 | 4/25/24 | - | - | - |
1CNY in Million2CNY
Estimates
Income Statement Evolution (Annual data)
| Fiscal Period: December | 2019 | 2020 | 2021 | 2022 | 2023 | 2024 | 2025 | 2026 |
|---|---|---|---|---|---|---|---|---|
| Net sales 1 | 9,990 | 11,912 | 15,001 | 16,110 | 20,367 | 23,029 | 29,749 | 30,684 |
| EBITDA 1 | 2,526 | 3,225 | 4,156 | - | 5,954 | 7,063 | 8,475 | 9,365 |
| EBIT 1 | 2,022 | 2,674 | 3,494 | 3,534 | 4,948 | 6,114 | 7,531 | 8,160 |
| Operating Margin | 20.24% | 22.45% | 23.29% | 21.94% | 24.29% | 26.55% | 25.32% | 26.59% |
| Earnings before Tax (EBT) 1 | 1,840 | 2,363 | 3,148 | 3,335 | 4,551 | 5,315 | 6,981 | 7,414 |
| Net income 1 | 1,379 | 1,724 | 2,323 | 2,524 | 3,359 | 3,891 | 5,254 | 5,487 |
| Net margin | 13.8% | 14.47% | 15.49% | 15.67% | 16.49% | 16.9% | 17.66% | 17.88% |
| EPS 2 | 0.1568 | 0.1932 | 0.2566 | 0.2807 | 0.3631 | 0.4180 | 0.5655 | 0.5896 |
| Free Cash Flow 1 | 1,339 | 2,455 | 2,596 | 3,110 | 4,418 | 5,124 | 5,147 | 5,964 |
| FCF margin | 13.4% | 20.61% | 17.31% | 19.31% | 21.69% | 22.25% | 17.3% | 19.44% |
| FCF Conversion (EBITDA) | 52.99% | 76.15% | 62.47% | - | 74.2% | 72.56% | 60.73% | 63.68% |
| FCF Conversion (Net income) | 97.09% | 142.44% | 111.75% | 123.22% | 131.52% | 131.7% | 97.96% | 108.69% |
| Dividend per Share 2 | 0.0527 | 0.0685 | 0.0710 | 0.0769 | 0.1500 | 0.1508 | 0.2013 | 0.2211 |
| Announcement Date | 2/28/20 | 4/22/21 | 4/25/22 | 4/25/23 | 4/25/24 | - | - | - |
1CNY in Million2CNY
Estimates
Income Statement Evolution (Quarterly data)
| Fiscal Period: December | 2021 Q4 | 2022 Q1 | 2022 Q2 | 2022 S1 | 2022 Q3 | 2022 Q4 | 2023 Q1 | 2023 Q2 | 2023 S1 | 2023 Q3 | 2023 Q4 | 2024 Q1 | 2024 Q2 | 2024 Q3 | 2024 Q4 | 2025 Q1 | 2025 Q2 |
|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|
| Net sales 1 | 3,404 | 4,169 | 3,939 | 8,107 | 4,944 | 3,058 | 5,021 | 5,231 | 10,252 | 5,795 | 4,320 | 5,196 | 5,773 | 6,713 | 5,020 | - | - |
| EBITDA | - | - | - | - | - | - | - | - | - | - | - | - | - | - | - | - | - |
| EBIT 1 | 468.5 | 908.1 | 1,024 | 1,932 | 1,474 | 128.8 | 1,154 | 1,369 | 2,522 | 1,920 | 505.3 | 1,233 | 1,485 | 2,043 | 1,141 | 1,513 | - |
| Operating Margin | 13.76% | 21.78% | 26% | 23.83% | 29.8% | 4.21% | 22.98% | 26.17% | 24.6% | 33.13% | 11.7% | 23.74% | 25.72% | 30.43% | 22.72% | - | - |
| Earnings before Tax (EBT) 1 | 375.6 | - | 937.4 | 1,827 | 1,397 | 110.8 | - | 1,283 | 2,416 | 1,883 | 252.1 | 1,203 | 1,547 | 1,798 | 994 | - | - |
| Net income 1 | 319.8 | - | 680.7 | 1,291 | 1,066 | 167.2 | - | 931.3 | 1,712 | 1,469 | 177.6 | 899.5 | 1,080 | 1,004 | 905.7 | - | - |
| Net margin | 9.39% | - | 17.28% | 15.93% | 21.56% | 5.47% | - | 17.8% | 16.7% | 25.35% | 4.11% | 17.31% | 18.72% | 14.96% | 18.04% | - | - |
| EPS 2 | 0.0355 | 0.0674 | 0.1000 | - | 0.1163 | 0.0154 | 0.0845 | 0.0988 | - | 0.1600 | 0.0200 | 0.0972 | 0.1153 | 0.1459 | 0.0971 | 0.1100 | 0.1400 |
| Dividend per Share 2 | 0.0710 | - | - | - | - | 0.0769 | - | - | - | - | - | - | - | - | 0.1418 | - | - |
| Announcement Date | 4/25/22 | 4/25/22 | 8/24/22 | 8/24/22 | 10/25/22 | 4/25/23 | 4/25/23 | 8/24/23 | 8/24/23 | 10/25/23 | 4/25/24 | 4/25/24 | - | - | - | - | - |
1CNY in Million2CNY
Estimates
Balance Sheet Analysis
| Fiscal Period: December | 2019 | 2020 | 2021 | 2022 | 2023 | 2024 | 2025 | 2026 |
|---|---|---|---|---|---|---|---|---|
| Net Debt 1 | 685 | - | - | - | - | - | - | - |
| Net Cash position 1 | - | 981 | 2,024 | 4,777 | 4,458 | 8,237 | 9,748 | 14,618 |
| Leverage (Debt/EBITDA) | 0.2711 x | - | - | - | - | - | - | - |
| Free Cash Flow 1 | 1,339 | 2,455 | 2,596 | 3,110 | 4,418 | 5,125 | 5,147 | 5,964 |
| ROE (net income / shareholders' equity) | 22.5% | 21.5% | 20.6% | 19.2% | 18.9% | 19.3% | 20.7% | 20.1% |
| ROA (Net income/ Total Assets) | 12.8% | 12.6% | 12.4% | - | - | 12.7% | 13.2% | 13.2% |
| Assets 1 | 10,761 | 13,718 | 18,695 | - | - | 30,687 | 39,801 | 41,569 |
| Book Value Per Share 2 | 0.7500 | 1.090 | 1.240 | 1.790 | 2.020 | 2.290 | 2.950 | 3.020 |
| Cash Flow per Share 2 | 0.2400 | 0.3700 | 0.4500 | 0.4800 | 0.6300 | 0.6600 | 0.7600 | 0.7700 |
| Capex 1 | 740 | 888 | 1,488 | 1,380 | 1,454 | 1,727 | 1,805 | 2,239 |
| Capex / Sales | 7.4% | 7.46% | 9.92% | 8.57% | 7.14% | 7.5% | 6.07% | 7.3% |
| Announcement Date | 2/28/20 | 4/22/21 | 4/25/22 | 4/25/23 | 4/25/24 | - | - | - |
1CNY in Million2CNY
Estimates
EPS & Dividend
Year-on-year evolution of the PER
Year-on-year evolution of the Yield
Change in Enterprise Value/EBITDA
Trading Rating
Investor Rating
ESG Refinitiv
B+
Sell
Buy
Mean consensus
BUY
Number of Analysts
20
Last Close Price
12.63
CNY
Average target price
21.32
CNY
Spread / Average Target
+68.80%
EPS Revisions
| 1st Jan change | Capi. | |
|---|---|---|
| -20.16% | 16.21B | |
| +4.50% | 12.44B | |
| +3.98% | 11.58B | |
| +9.72% | 10.79B | |
| +23.61% | 8.26B | |
| -2.19% | 7.68B | |
| +20.75% | 7.2B | |
| +4.49% | 6.67B | |
| +50.89% | 4.66B | |
| -4.50% | 4.21B |
- Stock Market
- Equities
- 300015 Stock
- Financials Aier Eye Hospital Group Co., Ltd.
